Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914379 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3337641 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02914379 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants.
The verdict
NCT02914379, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated. Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22). This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG [¹⁴C]-LY3337641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-09 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914379
The ClinicalTrials.gov registry entry for NCT02914379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3337641 is the first listed.
NCT02914379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02914379 about?
NCT02914379 is a clinical study titled "A Study of LY3337641 in Healthy Male Participants". The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated. Participants will be admitted to a clinical research unit (CRU) the day before dosing. ...
What is the current status of trial NCT02914379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-09. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02914379?
The interventions under investigation include: [¹⁴C]-LY3337641 (DRUG).
Who is sponsoring clinical trial NCT02914379?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.